Impact of gene expression profiling in lymphoma diagnosis and prognosis

Histopathology

Volumn 58, Issue 1, 2011, Pages 106-127

  Orsborne, Christopher ^a   Byers, Richard ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Diagnosis; Expression profiling; Lymphoma; Microarray; Prognosis

Indexed keywords

BONE MORPHOGENETIC PROTEIN 6; CD3 ANTIGEN; CD40 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; CHEMOATTRACTANT; CHLORDANE; CLUSTERIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; COMPLEMENTARY DNA; CYCLIN D2; CYCLOPHOSPHAMIDE; CYTOCHROME C OXIDASE; DOXORUBICIN; FLICE INHIBITORY PROTEIN; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN KINASE C; PROTEIN KINASE C BETA; PROTEIN KINASE C GAMMA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; RITUXIMAB; TRANSCRIPTION FACTOR FOXP3; UNINDEXED DRUG; UTROPHIN; VINCRISTINE;

B CELL LYMPHOMA; BURKITT LYMPHOMA; CLINICAL PRACTICE; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOMA; MICROARRAY ANALYSIS; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REGULATORY T LYMPHOCYTE; REVIEW; RNA ISOLATION; T CELL LYMPHOMA; WORLD HEALTH ORGANIZATION;

ANIMALS; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROGNOSIS;

EID: 78851469564     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03708.x     Document Type: Review

References (67)

1. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84; 1361-1392.
2. Swerdlow SH, Campo E, Harris NL. WHO classification of tumours of haematopoetic and lymphoid tissues. Lyon: IARC, 2008.
3. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286; 531-537.
4. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403; 503-511.
5. Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J. Clin. Oncol. 2002; 20; 1932-1941.
6. Saviozzi S, Calogero RA. Microarray probe expression measures, data normalization and statistical validation. Comp. Funct. Genomics 2003; 4; 442-446.
7. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl Acad. Sci. USA 1998; 95; 14863-14868.
8. Tamayo P, Slonim D, Mesirov J et al. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc. Natl Acad. Sci. USA 1999; 96; 2907-2912.
9. Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 2002; 8; 68-74.
10. Sommers CL, Rabin RL, Grinberg A, Tsay HC, Farber J, Love PE. A role for the Tec family tyrosine kinase Txk in T cell activation and thymocyte selection. J. Exp. Med. 1999; 190; 1427-1438.
11. Testi R, D'Ambrosio D, De Maria R, Santoni A. The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunol. Today 1994; 15; 479-483.
12. Ruegg CL, Rivas A, Madani ND, Zeitung J, Laus R, Engleman EG. V7, a novel leukocyte surface protein that participates in T cell activation. II. Molecular cloning and characterization of the V7 gene. J. Immunol. 1995; 154; 4434-4443.
13. Saeki H, Moore AM, Brown MJ, Hwang ST. Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J. Immunol. 1999; 162; 2472-2475.
14. Chang CC, McClintock S, Cleveland RP et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am. J. Surg. Pathol. 2004; 28; 464-470.
15. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103; 275-282.
16. Lossos IS, Czerwinski DK, Alizadeh AA et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N. Engl. J. Med. 2004; 350; 1828-1837.
17. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002; 346; 1937-1947.
18. Davies AJ, Rosenwald A, Wright G et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br. J. Haematol. 2007; 136; 286-293.
19. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl Acad. Sci. USA 2003; 100; 9991-9996.
20. Monti S, Savage KJ, Kutok JL et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105; 1851-1861.
21. Polo JM, Juszczynski P, Monti S et al. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc. Natl Acad. Sci. USA 2007; 104; 3207-3212.
22. Robertson MJ, Kahl BS, Vose JM et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol. 2007; 25; 1741-1746.
23. Lenz G, Wright GW, Emre NC et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc. Natl Acad. Sci. USA 2008; 105; 13520-13525.
24. Canepa ET, Scassa ME, Ceruti JM et al. INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life 2007; 59; 419-426.
25. Finoux AL, Chartrand P. Oncogenic and tumour suppressor microRNAs. Med. Sci. (Paris) 2008; 24; 1049-1054.
26. Myers MP, Pass I, Batty IH et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl Acad. Sci. USA 1998; 95; 13513-13518.
27. Martin-Subero JI, Kreuz M, Bibikova M et al. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 2009; 113; 2488-2497.
28. Ohm JE, McGarvey KM, Yu X et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 2007; 39; 237-242.
29. Schlesinger Y, Straussman R, Keshet I et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 2007; 39; 232-236.
30. Widschwendter M, Fiegl H, Egle D et al. Epigenetic stem cell signature in cancer. Nat. Genet. 2007; 39; 157-158.
31. Rooney N, Foster L, Byers RJ. Nodal B-cell lymphoma and Hodgkin lymphoma: current WHO classification and differential diagnostic dilemmas. Diagn. Histopathol. 2010; 16; 54-68.
32. Dave SS, Fu K, Wright GW et al. Molecular diagnosis of Burkitt's lymphoma. N. Engl. J. Med. 2006; 354; 2431-2442.
33. Linton K, Hey Y, Dibben S et al. Methods comparison for high-resolution transcriptional analysis of archival material on Affymetrix Plus 2.0 and Exon 1.0 microarrays. BioTechniques 2009; 47; 587-596.
34. Parker A, Bain B, Devereux S et al. BCSH guidelines: best practice in lymphoma diagnosis and reporting. British Committee for Standards in Haematology, Royal College of Pathologists, London, UK, 2010.
35. Dave SS, Wright G, Tan B et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 2004; 351; 2159-2169.
36. Byers RJ, Sakhinia E, Joseph P et al. Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood 2008; 111; 4764-4770.
37. Glas AM, Kersten MJ, Delahaye LJ et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105; 301-307.
38. Carreras J, Lopez-Guillermo A, Fox BC et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006; 108; 2957-2964.
39. Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, Gascoyne RD. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood 2010; 115; 289-295.
40. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008; 93; 193-200.
41. Focosi D, Petrini M. CD57 expression on lymphoma microenvironment as a new prognostic marker related to immune dysfunction. J. Clin. Oncol. 2007; 25; 1289-1291; author reply 1291-1292.
42. Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin. Cancer Res. 2007; 13; 388-397.
43. Curiel TJ, Coukos G, Zou L. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004; 10; 942-949.
44. Wahlin BE, Aggarwal M, Montes-Moreno S et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin. Cancer Res. 2010; 16; 637-650.
45. Lenz G, Wright G, Dave SS et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 2008; 359; 2313-2323.
46. Knoops L, Haas R, de Kemp S et al. In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. Blood 2007; 110; 1116-1122.
47. Nyman H, Adde M, Karjalainen-Lindsberg ML et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109; 4930-4935.
48. Rimsza LM, Leblanc ML, Unger JM et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008; 112; 3425-3433.
49. Natkunam Y, Farinha P, Hsi ED et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J. Clin. Oncol. 2008; 26; 447-454.
50. Malumbres R, Chen J, Tibshirani R et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 2008; 111; 5509-5514.
51. Byers R. Blocks to paraffin get the CHOP, +R. Blood 2008; 112; 3006-3007.
52. Martinez-Delgado B, Cuadros M, Honrado E et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia 2005; 19; 2254-2263.
53. Ballester B, Ramuz O, Gisselbrecht C et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 2006; 25; 1560-1570.
54. Piccaluga PP, Agostinelli C, Califano A et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res. 2007; 67; 10703-10710.
55. Dupuis J, Boye K, Martin N et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am. J. Surg. Pathol. 2006; 30; 490-494.
56. de Leval L, Rickman DS, Thielen C et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007; 109; 4952-4963.
57. Lamant L, de Reynies A, Duplantier MM et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 2007; 109; 2156-2164.
58. Chawla RK, Lawson DH, Sarma PR, Nixon DW, Travis J. Serum alpha-1 proteinase inhibitor in advanced cancer: mass variants and functionally inert forms. Cancer Res. 1987; 47; 1179-1184.
59. Jundt F, Raetzel N, Muller C et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005; 106; 1801-1807.
60. Cuadros M, Dave SS, Jaffe ES et al. Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J. Clin. Oncol. 2007; 25; 3321-3329.
61. Lamb J, Crawford ED, Peck D et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313; 1929-1935.
62. Cronin M, Sangli C, Liu ML et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin. Chem. 2007; 53; 1084-1091.
63. Rebsamen MC, Desmeules J, Daali Y et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J. 2009; 9; 34-41.
64. Sakhinia E, Glennie C, Hoyland JA et al. Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. Blood 2007; 109; 3922-3928.
65. Bortolin S. Multiplex phenotyping for thrombophilia-associated SNPs by universal bead arrays. Methods Mol. Biol. 2009; 496; 59-72.
66. National Institute for Clinical Excellence. Improving outcomes in haematological cancers. London, UK: NICE, 2003.
67. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 2010; 11; 685-696.